Grufity logoGrufity logo
StocksFundsSearch Filings

Zai Lab Ltd Stock Research

ZLAB

31.95USD+0.12(+0.38%)Market Closed

Market Summary

USD31.95+0.12
Market Closed
0.38%

ZLAB Alerts

ZLAB Stock Price

ZLAB RSI Chart

ZLAB Valuation

Market Cap

30.8B

Price/Earnings (Trailing)

-75.09

Price/Sales (Trailing)

133.22

EV/EBITDA

-74.56

Price/Free Cashflow

-83.63

ZLAB Price/Sales (Trailing)

ZLAB Profitability

Operating Margin

65.58%

EBT Margin

-206.04%

Return on Equity

-42.4%

Return on Assets

-36.33%

Free Cashflow Yield

-1.2%

ZLAB Fundamentals

ZLAB Revenue

Revenue (TTM)

231.1M

Revenue Y/Y

34.4%

Revenue Q/Q

0.31%

ZLAB Earnings

Earnings (TTM)

-410.0M

Earnings Y/Y

40.35%

Earnings Q/Q

20.44%

Price Action

52 Week Range

20.9853.95
(Low)(High)

Last 7 days

1.4%

Last 30 days

-7.8%

Last 90 days

-10.1%

Trailing 12 Months

6.5%

ZLAB Financial Health

Current Ratio

8.04

ZLAB Investor Care

Shares Dilution (1Y)

0.74%

Diluted EPS (TTM)

-0.42

Financials for Zai Lab

Income Statement (Last 12 Months)
Description(%) Q/Q2023Q12022Q42022Q32022Q22022Q1
Revenue7.5%231,114,000215,040,000196,611,000182,174,000170,933,000
  S&GA Expenses2.1%264,490,000258,971,000256,524,000248,971,000239,984,000
  R&D Expenses-1.9%281,026,000286,408,000391,548,000347,168,000423,308,000
EBITDA25.6%-434,838,000-584,637,000-520,108,000-545,684,000-
EBITDA Margin32.0%-2.02-2.97-2.86-3.19-
Earnings Before Taxes7.5%-410,036,000-443,065,000-592,612,000-527,494,000-552,482,000
EBT Margin31.6%-2.06-3.01-2.90-3.23-
Interest Expenses-0.00----
Net Income7.5%-410,036,000-443,286,000-593,342,000-528,564,000-553,955,000
Net Income Margin31.7%-2.06-3.02-2.90-3.24-
Free Cahsflow10.4%-392,227,000-437,894,000-472,046,000-493,213,000-
Balance Sheet
(In Millions)
Description(%) Q/Q2023Q12022Q42022Q32022Q22022Q1
Assets-4.1%1,1701,2201,2991,4191,501
  Current Assets-4.6%1,0721,1241,2101,3361,393
    Cash Equivalents-12.8%8801,0081,119681847
  Inventory21.5%38.0032.0029.0023.0020.00
  Net PPE0.8%58.0058.0051.0046.0045.00
Liabilities-3.3%169175193207193
  Current Liabilities-10.9%125140156169155
Shareholder's Equity-4.2%1,0011,0461,1061,2121,308
  Retained Earnings-2.6%-1,910-1,861-1,799-1,638-1,500
  Additional Paid-In Capital0.6%2,9112,8932,8772,8572,839
Accumulated Depreciation6.2%20.0019.0018.00--
Shares Outstanding0.4%964960960958957
Cashflow (Last 12 Months)
(In Millions)
Description(%) Q/Q2023Q12022Q42022Q32022Q22022Q1
Cashflow From Operations4.9%-349-367-411-445-466
  Share Based Compensation6.9%66.0061.0058.0050.0046.00
Cashflow From Investing-5.7%396420143-631-522
Cashflow From Financing-239.5%-5.87-1.73-1.81-2.99821

Risks for ZLAB

What is the probability of a big loss on ZLAB?

86.9%


Probability that Zai Lab stock will be more than 20% underwater in next one year

57.7%


Probability that Zai Lab stock will be more than 30% underwater in next one year.

41.9%


Probability that Zai Lab stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does ZLAB drawdown profile look like?

Y-axis is the maximum loss one would have experienced if Zai Lab was unfortunately bought at previous high price.

Drawdowns

Returns for ZLAB

Cumulative Returns on ZLAB

5.3%


5-Year Cumulative Returns

-22.1%


3-Year Cumulative Returns

What are the long-term rolling returns for ZLAB?

FIve years rolling returns for Zai Lab.

Annualized Returns

Which funds bought or sold ZLAB recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
2023-05-22
AMERIPRISE FINANCIAL INC
added
20.69
161,487
686,487
-%
2023-05-18
JPMORGAN CHASE & CO
added
212
6,688,000
9,495,000
-%
2023-05-18
INTERNATIONAL BIOTECHNOLOGY TRUST PLC
unchanged
-
202,922
2,626,140
0.73%
2023-05-18
NEW YORK STATE COMMON RETIREMENT FUND
reduced
-1.38
1,000
21,000
-%
2023-05-17
Advisory Services Network, LLC
unchanged
-
128
1,663
-%
2023-05-16
RBF Capital, LLC
unchanged
-
37,900
498,900
0.04%
2023-05-16
SUSQUEHANNA INTERNATIONAL GROUP, LLP
reduced
-48.19
-716,070
916,280
-%
2023-05-16
JANE STREET GROUP, LLC
sold off
-100
-746,194
-
-%
2023-05-16
Rockefeller Capital Management L.P.
sold off
-100
-
-
-%
2023-05-16
Susquehanna International Group Ltd.
new
-
958,121
958,121
0.54%

1–10 of 42

Latest Funds Activity

Are funds buying ZLAB calls or puts?
Calls
Puts
Are funds bullish or bearish(Calls - Puts)?
Net Call Options
No. of funds that own ZLAB
No. of Funds

Zai Lab News

MarketBeat
Clearbridge Investments LLC Grows Stock Holdings in Zai Lab ....
MarketBeat,
24 hours ago
Yahoo Finance
12 Best Chinese Stocks to Buy Now.
Yahoo Finance,
2 days ago
The Motley Fool
Investor's Business Daily

Schedule 13G FIlings of Zai Lab

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 14, 2023
qiming venture partners iv, l.p.
8.1%
79,229,320
SC 13G/A
Feb 13, 2023
capital world investors
0.6%
5,701,440
SC 13G/A
Feb 09, 2023
fmr llc
-
0
SC 13G/A
Feb 06, 2023
wellington management group llp
0.00%
0
SC 13G/A
Jul 05, 2022
baillie gifford & co
4.79%
46,935,800
SC 13G/A
Feb 14, 2022
qiming venture partners iv, l.p.
8.2%
7,922,932
SC 13G/A
Feb 14, 2022
du ying
4.78%
4,742,042
SC 13G/A
Feb 14, 2022
invesco ltd.
7.6%
7,286,493
SC 13G
Feb 11, 2022
capital world investors
5.5%
5,294,950
SC 13G/A
Feb 09, 2022
fmr llc
-
0
SC 13G/A

ZLAB Fair Value

Recent SEC filings of Zai Lab

View All Filings
Date Filed Form Type Document
May 09, 2023
10-Q
Quarterly Report
May 09, 2023
8-K
Current Report
May 01, 2023
ARS
ARS
Apr 28, 2023
DEF 14A
DEF 14A
Apr 18, 2023
PRE 14A
PRE 14A
Apr 05, 2023
4
Insider Trading
Apr 05, 2023
4
Insider Trading
Apr 05, 2023
4
Insider Trading
Apr 05, 2023
4
Insider Trading
Apr 05, 2023
4
Insider Trading

Latest Insider Trading transactions for ZLAB

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
2023-04-03
Cho William Ki Chul
acquired
-
-
2,827
chief financial officer
2023-03-31
Reinhart Harald
sold (taxes)
-35,222
33.26
-1,059
see remarks
2023-03-31
Edmondson Frazor Titus III
sold (taxes)
-31,696
33.26
-953
chief legal officer
2023-03-31
Du Ying
acquired
472,292
33.26
14,200
chairperson & ceo
2023-03-31
Du Ying
sold (taxes)
-185,857
33.26
-5,588
chairperson & ceo
2023-03-31
Reinhart Harald
acquired
144,614
33.26
4,348
see remarks
2023-03-31
Edmondson Frazor Titus III
acquired
116,410
33.26
3,500
chief legal officer
2023-03-06
Du Ying
gifted
-
-
-852
chairperson & ceo
2023-03-06
Du Ying
sold (taxes)
-4,902,740
40.55
-120,906
chairperson & ceo
2023-03-06
Du Ying
acquired
180,000
0.6
300,000
chairperson & ceo

1–10 of 50

About Zai Lab

Ying Du
1950
Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience primarily in Mainland China and Hong Kong. The company's commercial products include Zejula, a once-daily small-molecule poly polymerase 1/2 inhibitor; Optune, a device that delivers tumor treating fields; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; and Qinlock to treat gastrointestinal stromal tumors. It also develops Odronextamab to treat follicular lymphoma, diffuse large B-cell lymphoma, and other B-celllymphomas; Repotrectinib, a tyrosine kinase inhibitor (TKI) to target ROS1 and TRK A/B/C in TKI-naïve- or -pretreated cancer patients; Margetuximab for the treatment of breast and gastroesophageal cancers; Adagrasib for treating KRAS-G12C-mutated NSCLC, colorectal cancer, pancreatic cancer, and other solid tumors; and Bemarituzumab to treat gastric and gastroesophageal junction cancer. In addition, the company develops CLN-081 for the treatment of patients with EGFR exon 20 insertion NSCLC; Elzovantinib, an orally bioavailable multi-targeted kinase inhibitor; Tebotelimab, a tetravalent IgG4 monoclonal antibody; Retifanlimab that inhibits interactions between PD-1 and its ligands; ZL-2309, an orally active, selective, and ATP-competitive cell division cycle 7 (CDC7) kinase inhibitor; ZL-1201, a humanized IgG4 monoclonal antibody; Efgartigimod to reduce disease-causing immunoglobulin G antibodies; ZL-1102, a human nanobody targeting interleukin- 17A; KarXT for the treatment of psychiatric and neurological conditions; ZL-2313, an investigational inhibitor of triple-mutant EGFR harboring; ZL-2314, an investigational inhibitor of double-mutant EGFR harboring; and Sulbactam/durlobactam for the treatment of serious infections caused by Acinetobacter. Zai Lab Limited was incorporated in 2013 and is headquartered in Shanghai, China.

ZLAB Income Statement

2023-03-31
Unaudited Condensed Consolidated Statements of Operations - USD ($)
3 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Revenues:  
Product revenue, net$ 62,797,000$ 46,095,000
Collaboration revenue0629,000
Total revenues62,797,00046,724,000
Expenses:  
Cost of sales(21,337,000)(15,643,000)
Research and development(48,472,000)(53,854,000)
Selling, general, and administrative(62,510,000)(56,991,000)
Loss from operations(69,522,000)(79,764,000)
Interest income10,232,000188,000
Foreign currency gain8,912,0002,285,000
Other income (expenses), net1,234,000(4,882,000)
Loss before income tax and share of loss from equity method investment(49,144,000)(82,173,000)
Income tax expense00
Share of loss from equity method investment0(221,000)
Net loss(49,144,000)(82,394,000)
Net loss attributable to ordinary shareholders - basic(49,144,000)(82,394,000)
Net loss attributable to ordinary shareholders - diluted$ (49,144,000)$ (82,394,000)
Loss per share/ADS - basic (in dollars per share)$ (0.05)$ (0.09)
Loss per share/ADS - diluted (in dollars per share)$ (0.05)$ (0.09)
Weighted-average shares/ADSs used in calculating net loss per ordinary share/ADS - basic (in shares)961,444,780955,499,030
Weighted-average shares/ADSs used in calculating net loss per ordinary share/ADS - diluted (in shares)961,444,780955,499,030
American Depositary Shares  
Expenses:  
Loss per share/ADS - basic (in dollars per share)$ (0.51)$ (0.86)
Loss per share/ADS - diluted (in dollars per share)$ (0.51)$ (0.86)
Weighted-average shares/ADSs used in calculating net loss per ordinary share/ADS - basic (in shares)96,144,47895,549,903
Weighted-average shares/ADSs used in calculating net loss per ordinary share/ADS - diluted (in shares)96,144,47895,549,903

ZLAB Balance Sheet

2023-03-31
Unaudited Condensed Consolidated Balance Sheets - USD ($)
$ in Thousands
Mar. 31, 2023
Dec. 31, 2022
Current assets:  
Cash and cash equivalents$ 879,844$ 1,008,470
Short-term investments50,5500
Accounts receivable (net of allowance for credit loss of $13 and $11 as of March 31, 2023 and December 31, 2022, respectively)43,34639,963
Notes receivable17,3818,608
Inventories, net38,40531,621
Prepayments and other current assets42,77235,674
Total current assets1,072,2981,124,336
Restricted cash, non-current1,003803
Long term investments (including the fair value measured investment of $6,872 and $6,431 as of March 31, 2023 and December 31, 2022, respectively)6,8726,431
Prepayments for equipment1,7211,396
Property and equipment, net58,30957,863
Operating lease right-of-use assets20,14819,512
Land use rights, net6,9206,892
Intangible assets, net1,4791,511
Long-term deposits1,3241,396
Total assets1,170,0741,220,140
Current liabilities:  
Accounts payable66,36165,974
Current operating lease liabilities7,3187,050
Other current liabilities50,88166,818
Total current liabilities124,560139,842
Deferred income30,96821,360
Non-current operating lease liabilities12,97913,343
Other non-current liabilities3250
Total liabilities168,832174,545
Commitments and contingencies (Note 15)
Shareholders’ equity  
Ordinary shares (par value of $0.000006 per share; 5,000,000,000 shares authorized; 967,197,350 and 962,455,850 shares issued as of March 31, 2023 and December 31, 2022, respectively; 963,688,740 and 960,219,570 shares outstanding as of March 31, 2023 and December 31, 2022, respectively)66
Additional paid-in capital2,911,4542,893,120
Accumulated deficit(1,910,504)(1,861,360)
Accumulated other comprehensive income17,27225,685
Treasury Stock (at cost, 3,508,610 and 2,236,280 shares as of March 31, 2023 and December 31, 2022, respectively)(16,986)(11,856)
Total shareholders’ equity1,001,2421,045,595
Total liabilities and shareholders’ equity$ 1,170,074$ 1,220,140